ANTIDIABETIC DRUG APPROVED TO REDUCE RISK OF KIDNEY DISEASE

被引：0

作者：

Aschenbrenner, Diane S. ^{[1
,2
]}

机构：

[1] Notre Dame Maryland Univ, Baltimore, MD 21210 USA

[2] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA

来源：

AMERICAN JOURNAL OF NURSING | 2021年 / 121卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

引用

页码：25 / 25

页数：1

共 50 条

[41] Sickle Cell Disease Drug to interfere with the Pathogenesis approved in the EU
Freye, Reimund
TRANSFUSION MEDICINE AND HEMOTHERAPY, 2022, 49 (04) : 268 - 268
[42] Sickle Cell Disease Drug approved in EU to interfere with Pathogenesis
Freye, Reimund
ACTA HAEMATOLOGICA, 2022, 145 (05) : 573 - 573
[43] Drug approved for agitation associated with dementia due to Alzheimer disease
不详
NURSE PRACTITIONER, 2023, 48 (07): : 48 - 48
[44] Sickle Cell Disease Drug approved in the EU to Interfere with the Pathogenesis
Freye, Reimund
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (7-8)
[45] Drug Approved to Prevent Graft-vs-Host Disease
Voelker, Rebecca
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 327 (05): : 417 - 417
[46] Add-on Drug Approved for "Off" Episodes of Parkinson Disease
Voelker, Rebecca
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (13): : 1246 - 1246
[47] Miltefosine, an FDA-approved drug for the 'orphan disease', leishmaniasis
Berman, Jonathan
EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (06): : 727 - 735
[48] Liraglutide May Reduce Diabetic Kidney Disease
Slomski, Anita
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (16): : 1532 - 1532
[49] Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk
Toussaint, Nigel D.
Pedagogos, Eugenie
Tan, Sven-Jean
Badve, Sunil V.
Hawley, Carmel M.
Perkovic, Vlado
Elder, Grahame J.
NEPHROLOGY, 2012, 17 (05) : 433 - 444
[50] Immune Cell Therapy: Promising Approach to Reduce Chronic Kidney Disease Risk in Heart Failure
Humes, H. David
JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2025, 14 (05):

← 1 2 3 4 5 →